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Abstract
Background: Resistance among Klebsiella pneumoniae to most antibiotics is on the rise. Tigecycline has been
considered as one of the few therapeutic options available to treat multidrug-resistant bacteria. We investigated the
clinical and microbiological characteristics of tigecycline non-susceptible K. pneumoniae bacteremia.
Methods: Adult patients with tigecycline non-susceptible K. pneumoniae bacteremia at a medical center in Taiwan
over a 3-year period were enrolled. K. pneumoniae isolates were identified by the E-test using criteria set by the US
Food and Drug Administration (FDA). Data on the clinical features of patients were collected from medical records.
Genes for β-lactamases, antimicrobial susceptibilities and pulsed-field gel electrophoresis (PFGE) results were
determined for all isolates.
Results: Of 36 patients, 27 had nosocomial bacteremia. Overall 28-day mortality was 38.9%. The MIC50 and MIC90 of
tigecycline were 6 and 8 mg/L, respectively. No carbapenemase was detected among the 36 isolates. Twenty
isolates carried extended spectrum β-lactamases and/or DHA-1 genes. No major cluster of isolates was found
among the 36 isolates by PFGE. Intensive care unit onset of tigecycline non-susceptible Klebsiella pneumoniae
bacteremia was the only independent risk factor for 28-day mortality.
Conclusions: The high mortality of patients with tigecycline non-susceptible K. pneumoniae bacteremia may
suggest a critical problem. Further study to identify the possible risk factors for its development and further
investigation of this type of bacteremia is necessary.
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Background
Klebsiella pneumoniae is a common cause of community-
acquired and hospital-acquired Gram-negative infection of
the bloodstream [1]. The vast majority of K. pneumoniae
infections (including urinary-tract infections, pneumo-
nia, and intra-abdominal infections) are associated with
hospitalization [2]. In Taiwan, K. pneumoniae is also a major
cause of community-acquired pyogenic infection [3-7].
K. pneumoniae strains harboring extended spectrum
β-lactamases (ESBL) and, more recently, carbapenemase
that confer resistance to multiple antibiotics, have been
described in many parts of the world. These multidrug-
resistant (MDR) organisms affect the choice of antimicro-
bial therapy, and are a major cause for increasing hospital
costs and duration of hospitalizations [8].
Tigecycline is an expanded broad-spectrum antibiotic
representing a new class called “glycylcyclines”. In compari-
son with other tetracyclines, tigecycline displays higher
in vitro activity against several Gram-positive and various
Gram-negative microorganisms (including MDR strains).
Resistance among K. pneumoniae to most antibiotics is on
the rise globally [9]. However, tigecycline remains active
against many strains, and regarded as one of the few
therapeutic options available for treating MDR bacteria.
Tigecycline resistance in K. pneumoniae has increasingly
been reported in European countries, with a non-susceptible
prevalence of 7.5–50% [10]. Reports from North America,
South America and Asia have demonstrated that the
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non-susceptible prevalence is <10% [10]. The increasing
prevalence of tigecycline resistance is a growing concern
clinically. However, reports of patients infected with
tigecycline- resistant K. pneumoniae have rarely been
identified [11-14]. Furthermore, no study has systematically
analyzed clinical data on tigecycline non-susceptible isolates
causing bloodstream infection in adult patients.
We investigated the clinical and microbiological charac-
teristics of bacteremia caused by tigecycline non-susceptible
K. pneumoniae in adult patients during 2010–2012 from a
medical center in Taiwan.
Methods
Study population
This retrospective study was conducted at Taipei Veterans
General Hospital (a 2900-bed tertiary-care teaching hos-
pital) from January 2010 to December 2012. The clinical
and microbiological data of all consecutive patients with ≥1
positive blood culture for K. pneumoniae strains showing
non-susceptibility to tigecycline (minimum inhibitory
concentration (MIC) > 2 mg/L) were collected. For patients
with more than 2 positive blood cultures, only the first
blood culture was included. Patients <20 years of age and
those with incomplete medical records were excluded. All
clinical isolates were taken as part of standard care. The
study protocol was approved by the Review Board of
Taipei Veterans General Hospital (Taipei, Taiwan).
Strain identification and antimicrobial susceptibility test
Identification and antimicrobial susceptibility of K. pneumo-
niae were determined using the Vitek2 system (bioMérieux,
Marcy-l’Etoile, France). Antimicrobial susceptibility was
interpreted according to the guidelines of the Clinical and
Laboratory Standards Institute (CLSI) [15]. K. pneumo-
niae strains showing non-susceptibility to tigecycline
(MIC >2 mg/L) according to the Vitek2 system were
tested further by the E-test method (AB Biodisk, Solna,
Sweden) according to manufacturer instructions. Break-
points for tigecycline were those set by the US Food and
Drug Administration (FDA) (2 and 8 mg/L for susceptible
and resistant, respectively) [16]. Escherichia coli ATCC
25922, E. coli ATCC 35218 and Pseudomonas aeruginosa
ATCC 27853 were used as control strains in the suscepti-
bility assays.
Molecular characterization of β-lactamases
All tigecycline non-susceptible strains were tested by
polymerase chain reaction (PCR) amplification and DNA
sequencing for various carbapenemase genes (encoding
class-B families IMP, VIM, NDM-1, GIM, SPM and SIM;
class-A families NMC, IMI, SME, KPC and GES; and
class-D family OXA-48), plasmid-borne ampC-like genes
(encoding CMY, DHA and ACT) and ESBL genes (encoding
CTX-M, TEM, and SHV) using methodology and primers
described previously [17].
Capsular genotype
To determine the capsular genotypes of K. pneumoniae,
we undertook cps genotyping by the PCR detection of K
serotype-specific alleles at wzy and wzx loci, including
serotypes K1, K2, K5, K20, K54, and K57, as described
previously [18]. These capsular serotypes are regarded as
having the highest association with an invasive disease
or pathogenicity [19].
Pulsed-field gel electrophoresis (PFGE)
Total DNA was prepared and PFGE was conducted as
described previously [17]. Restriction enzyme XbaI (New
England BioLabs, Ipswich, MA, USA) was used at the
temperature suggested by the manufacturer. Restriction
fragments were separated by PFGE in 1% agarose gel
(Bio-Rad, Hercules, CA, USA) in 0.56 TBE buffer (45 mM
Tris, 45 mM boric acid, 1.0 mM ethylenediamine tetra-
acetic acid (EDTA); pH 8.0) for 22 h at 200 V and 14°C
and with ramp times of 2–40 s using CHEF Mapper
apparatus (Bio-Rad). Gels were then stained with ethidium
bromide and photographed under ultraviolet light. The
Dice coefficient was used to calculate similarities. The
unweighted pair-group method with arithmetic mean
(UPGMA) was used for cluster analyses by BioNumerics
ver5.10 (Applied Maths, Austin, TX, USA).
Data collection
Medical records were reviewed to extract pertinent infor-
mation, including demographic characteristics; comorbid
conditions and the Charlson Comorbidity Index [20],
duration of hospital stay, duration of therapy with individual
antimicrobial drugs, antimicrobial therapy administrated
before the onset of bacteremia, and a ventilator, central
venous catheter, or a Foley catheter at the time of bac-
teremia onset. The onset of bacteremia was defined as the
day the blood culture that eventually yielded K. pneumoniae
was obtained. Bacteremia was defined as nosocomial-
acquired if the index blood culture was collected >48 h
after hospital admission and no signs or symptoms of
infection was noted upon hospital admission. Infections
with onset ≤48 h after hospital admission were classified as
healthcare-associated or community-acquired in accord-
ance with definitions described previously [6]. Episodes of
bacteremia were considered acquired in the intensive care
unit (ICU) if they appeared >48 h after ICU admission. In-
fection severity was evaluated using the Acute Physiology
and Chronic Health Evaluation (APACHE) II score and
Pitt Bacteremia Score described within 24 h before the
onset of bacteremia [21,22]. Appropriate antimicrobial
therapy was defined as administration of ≥1 antimicrobial
agent to which the causative pathogen was susceptible
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in vitro within 48 h after the onset of bacteremia with
an approved route and dose appropriate for end-organ
function. Antimicrobial therapy that did not meet this
definition was considered inappropriate. The primary
outcome measure was all-cause 28-day mortality after
the onset of K. pneumoniae bacteremia.
Statistical analyses
Categorical variables are absolute numbers and their
relative frequencies. Quantitative variables are mean
and standard deviation (SD) if distributed normally, or
as median and interquartile range (IQR) if distributed
non-normally. Contingency data were analyzed by the
two-tailed chi-square test or the Fisher’s exact test.
Continuous data were analyzed by the Student’s t-test or
the Mann–Whitney U test. An exact logistic regression
was used in the multivariate analyses to analyze risk factors
for 28-day mortality. All factors with p < 0.1 in the univari-
ate analyses were included in the exact logistic regression.
p < 0.05 was considered as significant. Statistical analyses




During the study period, 40 patients with bacteremia
due to tigecycline non-susceptible K. pneumoniae were
identified. Thirty-six patients were finally enrolled after
confirmation of susceptibility by the E-test method. The
MIC50 and the MIC90 of tigecycline were 6 and 8 mg/L,
respectively. The tigecycline non-susceptibility rate for
K. pneumoniae bacteremia during the study period was
0.05%. The in vitro activities of the tested antimicrobial
agents against the 36 tigecycline non-susceptible K.
pneumoniae isolates are shown in Table 1. Among the
36 isolates, 8 isolates were not susceptible to ertapenem
(MIC ≥1 μg/mL). Of the 8 isolates not susceptible to erta-
penem, 5 isolates were resistant to ertapenem (MIC ≥2 μg/
mL) and two of them were not susceptible to imipenem
(MIC = 2 and 4 μg/mL, respectively).
One pair of K. pneumoniae strains had indistinguishable
PFGE patterns (Figure 1). According to criteria described
previously, no major cluster of isolates was found among
those 36 isolates.
Carbapenemase genes were not detected among any of
the 36 isolates. Among the isolates producing ESBLs,
blaCTX-M was detected in 6 isolates. Five isolates expressed
CTX-M-15, and 1 isolate expressed CTX-M-14. blaSHV-11,
blaSHV-12 and blaSHV-31 were detected in 7, 3, and 2 isolates,
respectively. With regard to AmpC-type β-lactamases,
blaDHA-1 was detected in 18 isolates, and blaCMY-2 and
blaACT-1 were not detected among these isolates (Table 2).
The results of capsular genotyping for the 6 genotypes
(K1, K2, K5, K20, K54 and K57) showed that 2 isolates
belonged to capsular type K2, and that 1 isolate was
capsular type K54. These 3 isolates did not carry ESBL
or plasmid-borne ampC-like genes.
Clinical characteristics
During the study period, no obvious increasing trends or
any cluster of tigecycline non-susceptible K. pneumoniae
bacteremia was identified. There was no epidemiological
relationship between the 2 patients whose isolates had
indistinguishable patterns on PFGE. The usage of tigecyc-
line was 11.89 defined daily doses per 1000 patient-days.
The clinical characteristics of the patients are summarized
in Table 3. Of these patients, 27 (75%) acquired nosocomial
K. pneumoniae bacteremia, and 14 patients (38.9%) ac-
quired K. pneumoniae bacteremia in the ICU. Among the
9 patients with community-onset bacteremia, 6 patients
(16.7%) were categorized as having healthcare-associated
bacteremia. Most patients received antibiotics during the
last 30 days. However, only 13 patients (36.1%) received
tigecycline. We investigated further the previous culture-
positive data for tigecycline-susceptible K. pneumoniae
and associated tigecycline use in the past 90 days. Nine pa-
tients with tigecycline-susceptible K. pneumoniae isolates
were identified, and 2 patients with tigecycline-susceptible
K. pneumoniae isolated within 30 days before bacteremia
has been treated with tigecycline.
Pneumonia, intra-abdominal infection, and biliary-tract
infection (BTI) were the common sources of bacteremia.
The clinical syndromes of patients infected with the
Table 1 In vitro activities of tested antimicrobial agents















Tigecycline 3-32 6 8
Ciprofloxacin <0.25 to >4 2 >4 15 (42)
Levofloxacin 0.5 to >8 >8 >8 14 (39)
Ampicillin-sulbactam 8 to >32 >32 >32 2 (6)
Piperacillin-tazobactam* 8 to >128 32 >128 12 (48)
Cefazolin <1 to >64 >64 >64 13 (36)
Ceftriaxone <1 to >64 <1 >64 21 (58)
Ceftazidime <1 to >64 16 >64 16 (44)
Cefepime <1 to >64 <1 >64 23 (64)
Amikacin <2 to >64 <2 16 33 (92)
Gentamicin <1 to >16 <1 >16 22 (61)
Ertapenem <0.5 to >8 <0.5 4 28 (78)
Imipenem <0.25 to 4 <1 <1 34 (94)
aMIC: minimal inhibitory concentration.
bMIC50: MIC for 50% of isolates.
cMIC90: MIC for 90% of isolates.
*Total number is 25 because 11 patients did not undergo the MIC test.
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capsular type-K2 strain were pneumonia and BTI. BTI was
evident in the patient infected with the capsular type K54.
The treatment regimen after the sensitivity reports were
available included: 13 patients received carbapenem, 11
patients received cephalosporins, 4 patients received fluoro-
quinolones, and 2 patients received β-lactam/β-lactamase
inhibitors. The remaining 6 patients died before the
sensitivity reports were available. Among these 6 patients,
4 patients received tigecycline, and 2 patients received
carbapenem empirically. The overall 28-day mortality
among patients infected with tigecycline non-susceptible
K. pneumoniae was 38.9%.
Univariate analyses of the factors associated with 28-day
mortality are shown in Table 4. The exact logistic regres-
sion model showed that the only independent risk factor
for 28-day mortality is ICU onset of tigecycline non-
susceptible Klebsiella pneumoniae bacteremia (odds
ratio (OR) 13.46, 95% confidence interval (CI) 1.35–637.17,
p = 0.021).
Discussion
We demonstrated here, for the first time, the clinical
and microbiological characteristics of tigecycline non-








































Figure 1 Pulse-field gel electrophoresis dendrogram of 36 K. pneumoniae isolates. Most of the isolates did not have a clonal relationship.
Isolates 317 and 398 showed identical patterns.
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patients had nosocomial bacteremia, and the overall
28-day mortality was 38.9%. The MIC50 and MIC90 of
tigecycline were 6 and 8 mg/L, respectively. Among all
isolates, 18 were ESBL producers, and DHA-1 was
detected in 18 isolates. No carbapenemase genes were
detected among all 36 isolates. According to the results of
PFGE, most isolates were epidemiologically unrelated.
Interpretive criteria for the in vitro susceptibility testing
of tigecycline are based on the breakpoints approved by the
FDA or on those published by the European Committee on
Antimicrobial Susceptibility Testing. The CLSI has not
released tentative or approved guidelines. Differences in
susceptibility results according to the MIC interpretive
criteria of the two guidelines as well as the testing methods
used have been emphasized in several reports [23]. One
recent study questioned the performance of the Vitek2
automated system to reliably determine the susceptibility of
Enterobacteriaceae species other than E. coli to tigecycline
[23]. Moreover, it has been reported that the E-test shows
the best correlation with the broth microdilution method,
and exhibits lowest error rates as well as highest essential
agreement and categorical agreement [24]. In general, the
Vitek2 automated system produces higher MIC values than
E-test doses, which can potentially result in false resistance
findings using the former approach [24]. E-test susceptibil-
ity results obtained using the FDA criteria could be consid-
ered as a reliable method for tigecycline testing, as shown
previously [25]. In the current study, isolates reported as
being non-susceptible to tigecycline by the Vitek2 system
were confirmed with the E-test method to avoid the mis-
classification of the results.
Common sources of bacteremia in our study include
infections of the lower respiratory tract, BTI, and intra-
abdominal infections. One report suggested that clinicians
should be aware of the potential risk for treatment-induced
tigecycline resistance, especially if urine is the main source
of bacteria [22]. In contrast to that report, we identified
only 1 case with a urinary-tract infection. Physicians should
recognize that the emergence of tigecycline non-susceptible
K. pneumoniae bacteremia can be associated with various
syndromes.
The mechanisms of resistance mediating the effectiveness
of tigecycline have been attributed to RNDtype transporters
and other efflux pumps [10]. Analyses of clinical studies
suggest that long-term tigecycline monotherapy may carry
a higher risk for developing tigecycline resistance [10].
One recent study investigating non-susceptibility in K.
pneumoniae and E. coli isolates causing neonatal septi-
cemia found increasing tigecycline MIC values from 2007
to 2010. This increase cannot be attributed to the use of
tigecycline because of the restricted use of this antibiotic
in their hospital. The author suggested that the elevated
MIC of tigecycline might be attributed indirectly to the
use of other antibiotics that are also effluxed through the
AcrAB–TolC pump [14]. In the current study, although
most patients received one or more antibiotics in the
past 30 days, only 36.1% of subjects were treated with
tigecycline in the past 30 days. Further study to analyze the
risk factors for tigecycline non-susceptible K. pneumoniae
infection is necessary.
In the present study, PFGE analyses revealed that tige-
cycline non-susceptible K. pneumoniae isolates causing
bacteremia were not clonal in Taiwan. This implies that the
acquisition of tigecycline non-susceptibility in invasive K.
pneumoniae isolates was most likely through independent
mechanisms. Such non-clonal occurrence of tigecycline
non-susceptibility in invasive K. pneumoniae isolates
suggests that tigecycline resistance may be due to selective
pressure, including increasing, inappropriate and inad-
equate use of antibiotics. Antibiotic stewardship will be
essential for helping us understand whether this holds true
in real-life situations.
The 28-day mortality among patients with tigecycline
non-susceptible K. pneumoniae bacteremia was 38.9%.
The case mortality of K. pneumoniae bacteremia has been
found to be ≈20% [1]. With respect to drug-resistant
Table 2 Molecular characteristics of the 22 tigecycline
non-susceptible K. pneumoniae isolates with ceftriaxone





TEM SHV CTX-M DHA-1
1 3 <0.5 — SHV-1 — +
2 3 <0.5 — SHV-12 — +
3 3 8 — -a — —
4 3 <0.5 TEM-1 SHV-11 — —
5 4 <0.5 TEM-1 SHV-11 CTXM-15 +
6 4 2 — SHV-1 CTXM-15 +
7 4 <0.5 — SHV-12 — +
8 4 <0.5 — SHV-31 — +
9 4 <0.5 TEM-1 SHV-2 — —
10 4 1 TEM-1 SHV-1 CTXM-15 +
11 6 8 — SHV-2 — +
12 6 4 — SHV-1 — +
13 6 <0.5 TEM-1 SHV-1 CTXM-15 +
14 6 <0.5 TEM-1 SHV-1 CTXM-15 +
15 6 <0.5 TEM-1 SHV-11 — +
16 6 1 TEM-1 SHV-11 — +
17 8 1 TEM-1 SHV-11 CTXM-14 +
18 8 <0.5 — SHV-12 — +
19 8 <0.5 — —a — +
20 8 8 — SHV-31 — —
21 16 <0.5 — SHV-11 — +
22 32 <0.5 TEM-1 SHV-11 — +
aThe result showed OPK-B.
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K .pneumoniae bacteremia, the mortality in those with
carbapenem-resistant K. pneumoniae bacteremia is ≈40–
50% [21,26-28], and ≈20–30% in ESBL-producing K.
pneumoniae bacteremia [21,22]. The present report is
the first to point out high mortality among patients with
tigecycline non-susceptible K. pneumoniae bacteremia in
Taiwan. One recent study found that most (75%) of the
tigecycline resistant K. pneumoniae were Klebsiella pneu-
moniae carbapenemase producers [29]. Surprisingly, no
carbapenemase-producing K. pneumoniae were identified
in the current study. The emergence of tigecycline non-
susceptible K. pneumoniae bacteremia, in addition to carba-
penem resistance, may become an imminent issue in the
foreseeable future. We also found that the ICU onset of
tigecycline non-susceptible K. pneumoniae bacteremia was
an independent risk factor for 28-day mortality. Resistance
to tigecycline could be simply a marker of disease severity
as shown in infections caused by other resistant microor-
ganisms. In addition, we identified 3 isolates belonging to
the capsular serotypes K2 and K54, which are thought to
be associated most closely with an invasive disease and/or
pathogenicity. The MDR K. pneumonaie strains rarely
belonged to the virulent capsular types (K1, K2, K5,
K20, K54, and K57). It would be of interest to study the
relationship between these capsular types and tigecycline
non-susceptible strains.
Table 3 Characteristics of 36 adult patients with
tigecycline non-susecptible K. pneumoniae bacteremia
Characteristic n (%)
Age (years, median, IQR) 75.5, 63.5–81.7
Male sex 27 (75)
Underlying disease
Immunosuppressiona 9 (25)
Diabetes mellitus 18 (50)
Chronic obstructive lung disease 5 (13.9)
Cerebral vascular disease 10 (27.8)
Chronic kidney disease, stage = 4 or 5 13 (36.1)
Hemodialysis 11 (30.6)
Malignancy 14 (38.9)
Hematological malignancy 3 ( 8.3)
Solid tumor 11 (30.6)
Liver cirrhosis 3 (8.3)
Charlson comorbidity score (median, IQR) 3, 2–6
Community-acquired infections 3 ( 8.3)
Healthcare-associated infectionsb 6 (16.7)
Nosocomial infectionsb 27 (75)
ICU 14 (38.9)
Medical ward 8 (22.2)
Surgical ward 5 (13.9)
Polymicrobial infection 2 (5.6)




β-lactams plus β-lactamase inhibitors 12 (33.3)
First- and second-generation cephalosporins 11 (30.6)




Ward, duration of stay and devices at the time
of bacteremia
Acquired after ICU >48 h 14 (38.9)
Days of hospitalization before bacteremia
(median, IQR)
48, 18–82
Urinary catheter 17 (47.2)
Central venous catheter 23 (63.9)
Mechanical ventilation 18 (50)
Pitt bacteremia score (mean ± SD) 4 ± 4
APACHE II score (mean ± SD) 23 ± 10
Infection sources and clinical syndrome
Pneumonia 10 (27.8)
Table 3 Characteristics of 36 adult patients with
tigecycline non-susecptible K. pneumoniae bacteremia
(Continued)
Intra-abdominal infection other than
biliary-tract infection
5 (13.9)
Biliary-tract infection 7 (19.4)
Skin and soft-tissue infection 2 (5.6)
Catheter infection 1 (2.8)
Urinary-tract infection 1 (2.8)
Unknown primary focus 10 (27.8)
Appropriate antibiotic treatment 17 (47.2)
Outcome
Presentation with septic shock 19 (52.8)
Requiring admission to ICU after bacteremia 19 (52.8)
In-hospital death 17 (47.2)
28-day mortality 14 (38.9)
IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology
and Chronic Health Evaluation; SD, standard deviation.
aImmunosuppression includes patients who underwent solid-organ
transplantation, corticosteroid therapy, and immunosuppression therapy.
bBacteremia was defined to be nosocomial-acquired if the index blood culture
was collected >48 h after hospital admission and no signs or symptoms of
infection were noted at hospital admission. Bacteremia with onset ≤48 h after
hospital admission was classified as healthcare-associated infection if patients
met any of the following criteria: having received intravenous therapy at home
or in an outpatient clinic during the past 30 days; having received renal dialysis in
a hospital or clinic during the past 30 days; having hospitalized for 2 or more days
during the past 90 days; or having resided in a nursing home or long-term
care facility.
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Our study had several limitations. The important limita-
tions were inherent to its retrospective design and the
limited number of occurrence in a single institution. Cau-
tion must be taken to interpret data from a small number
of cases. In addition, our study did not include a control
group to identify specific risk factors or to compare the
prognostic implications. Finally, we did not investigate the
possible mechanism (e.g., overexpression of different efflux
pumps) among these K. pneumoniae isolates. Nevertheless,
our study was the first to describe the characteristics of
tigecycline non-susceptible K. pneumoniae bacteremia
in Taiwan, and will provide an important foundation for
further work in this emerging area of interest.
Conclusion
The high mortality of patients with tigecycline non-
susceptible K. pneumoniae bacteremia may indicate a
critical clinical problem. The emergence of tigecycline
non-susceptible K. pneumoniae bacteremia in our hospital
merits further studies to identify potential risk factors for
its development.
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Table 4 Risk factors for 28-day mortality among 36 patients infected by tigecycline non-susecptible K. pneumoniae
bacteremia
Survivors
(n = 22), n (%)
Non-survivors
(n = 14), n (%)
p Adjustedpa
Age (years, median, IQR) 76.5, 69.3–84.3 71, 60.3–79 0.175
Male sex 17 (77.3) 10 (71.4) 0.988
Underlying disease
Immunosuppressionb 5 (22.7) 4 (28.6) 0.988
Diabetes mellitus 9 (40.9) 9 (64.3) 0.305
Chronic obstructive lung disease 2 (9.1) 3 (21.4) 0.574
Hemodialysis 5 (22.7) 6 (42.9) 0.364
Malignancy 7 (31.8) 7 (50) 0.458
Liver cirrhosis 2 ( 9.1) 1 (7.1) 1.000
Cerebral vascular disease 6 (27.3) 4 (28.6) 1.000
Charlson comorbidity score (median, IQR) 3, 2–5 4, 3–8.3 0.171
Pitt bacteremia score (mean ± SD) 3.3 ± 3.1 5.9 ± 3.7 0.037 0.847
APACHE II score (mean ± SD) 20.1 ± 0.6 27.6 ± 11.0 0.016 0.958
Acquired after ICU >48 h 3 (13.6) 11 (78.6) <0.001 0.021
Infection sources and clinical syndrome
Pneumonia 3 (13.6) 7 (50) 0.047 0.569
Intra-abdominal infection other than
biliary-tract infection
2 (9.1) 3 (21.4) 0.574
Biliary-tract infection 7 (31.8) 0 (0)
Unknown primary focus 8 (36.4) 2 (14.3) 0.289
Presentation with septic shock 9 (40.9) 10 (71.4) 0.147
Appropriate antibiotic treatment 12 (54.6) 6 (42.9) 0.733
Ertapenem non-susceptibility 6 (27.3) 2 (14.3) 0.628
Tigecycline MIC >4 μg/mL 10 (45.5) 8 (57.1) 0.733
Tigecycline MIC >6 μg/mL 4 (18.2) 6 (42.9) 0.220
ESBL-producing strain 10 (45.5) 8 (57.1) 0.733
IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.
aAll factors with p < 0.1 in univariate analyses were included in the exact logistic regression.
bImmunosuppression includes patients who underwent solid-organ transplantation, corticosteroid therapy, and immunosuppression therapy.
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